HHV-8 K-bZIP (F33P1) Antibody from Santa Cruz Biotechnology, Inc.

Yes, the HHV-8 K-bZIP (F33P1) antibody has been utilized in studies investigating the lytic cycle of Kaposi's sarcoma-associated herpesvirus (KSHV) in endothelial cells. For instance, it was employed in Western blot analyses to detect K-bZIP expression during KSHV reactivation, highlighting its role in the viral life cycle (gabaev2020).

The HHV-8 K-bZIP antibody has been shown to work effectively in immunofluorescence assays. It was used to visualize K-bZIP protein expression in KSHV-infected cells, demonstrating its utility in studying viral protein localization and expression patterns during infection (gonnella2024).

This antibody targets the K-bZIP protein of KSHV, which is involved in the regulation of viral gene expression and the lytic cycle. Studies have indicated that K-bZIP plays a role in modulating host cell responses and may contribute to the oncogenic potential of KSHV, making this antibody valuable for research into KSHV-associated malignancies (gilardin2020).

The HHV-8 K-bZIP antibody has been cited in research exploring the mechanisms by which KSHV induces tumorigenesis, including its effects on macrophage polarization and cytokine release. This suggests that the antibody can be instrumental in understanding the viral contributions to KSHV-associated cancers, such as Kaposi's sarcoma (gilardin2020).